In contrast to prior work demonstrating the importance of stromal cGAS–STING signaling in regulating the anti-tumor response to DNA-damaging therapies, this group demonstrated that the anti-tumor effects of olaparib required tumor cell cGAS–STING activation. This evidence concerns the gene CGAS and neoplasm.